Alpha Tau Medical (NASDAQ:DRTS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS) in a research report report published on Tuesday, Benzinga reports. The brokerage currently has a $9.00 price objective on the stock. HC Wainwright also issued estimates for Alpha Tau Medical’s FY2024 earnings at ($0.47) EPS.

Separately, Piper Sandler restated an overweight rating and issued a $7.00 price target on shares of Alpha Tau Medical in a research report on Thursday, August 15th.

Alpha Tau Medical Stock Down 1.3 %

NASDAQ DRTS opened at $2.20 on Tuesday. The firm has a market cap of $153.28 million, a PE ratio of -5.37 and a beta of 0.75. The company has a debt-to-equity ratio of 0.07, a current ratio of 11.60 and a quick ratio of 11.60. The stock’s 50 day simple moving average is $2.17 and its 200 day simple moving average is $2.57. Alpha Tau Medical has a one year low of $1.75 and a one year high of $3.90.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Levin Capital Strategies L.P. lifted its holdings in Alpha Tau Medical by 2.6% during the first quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock worth $999,000 after acquiring an additional 8,641 shares in the last quarter. Aptus Capital Advisors LLC lifted its holdings in Alpha Tau Medical by 83.7% during the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares in the last quarter. Financial Guidance Group Inc. lifted its holdings in Alpha Tau Medical by 83.7% during the second quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares in the last quarter. USAdvisors Wealth Management LLC bought a new position in Alpha Tau Medical during the first quarter worth about $30,000. Finally, Caprock Group LLC bought a new position in Alpha Tau Medical during the second quarter worth about $59,000. 2.65% of the stock is currently owned by institutional investors.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.